SBL
BDTX icon

Sargent Bickham Lagudis’s Black Diamond Therapeutics BDTX Stock Holding History

Sargent Bickham Lagudis’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100
Closed -$2K – 931
2021
Q1 		$2K Hold
100
– – ﹤0.01% 851
2020
Q4 		$3K Hold
100
– – ﹤0.01% 772
2020
Q3 		$3K Buy
+100
New +$3.04K ﹤0.01% 694

Other funds holding BDTX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sargent Bickham Lagudis's BDTX Position: Q2 2021 in Review

Sargent Bickham Lagudis sold out of Black Diamond Therapeutics (BDTX) in Q2 2021, closing a stake of 100 shares — an estimated $2K sold.

Sargent Bickham Lagudis first reported a position in BDTX in Q3 2020 and held it in 3 quarters. The position peaked at $3K in Q4 2020. 102 funds tracked by Wall St. Rank hold BDTX as of Q2 2021.

  • Sargent Bickham Lagudis reported no remaining Black Diamond Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 100 Black Diamond Therapeutics shares in Q2 2021, an estimated $2K.
  • Sargent Bickham Lagudis first reported a position in Black Diamond Therapeutics in Q3 2020 and held it in 3 quarters.
  • Sargent Bickham Lagudis's Black Diamond Therapeutics position peaked at $3K in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q2 2021, filed 19 Jul 2021.